{"id":"rhepo","safety":{"commonSideEffects":[{"rate":"null","effect":"Thromboembolism"},{"rate":"null","effect":"Increased risk of death, myocardial infarction, stroke, and thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"rhEPO, or recombinant human erythropoietin, is a glycoprotein that mimics the action of endogenous erythropoietin. It binds to the erythropoietin receptor on the surface of erythroid progenitor cells, stimulating their proliferation and differentiation into mature red blood cells. This results in an increase in red blood cell mass and hemoglobin levels.","oneSentence":"rhEPO stimulates erythropoiesis by binding to the erythropoietin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:22.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia associated with chemotherapy"}]},"trialDetails":[{"nctId":"NCT06854276","phase":"PHASE2","title":"Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-03-01","conditions":"Chemotherapy-induced Anemia, Non-myeloid Malignancies","enrollment":80},{"nctId":"NCT03409107","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-05","conditions":"Anaemia","enrollment":614},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT02708914","phase":"PHASE3","title":"Study to Compare the Safety and Efficacy of UB-851 and Eprex®","status":"COMPLETED","sponsor":"UBI Pharma Inc.","startDate":"2016-03","conditions":"Renal Anemia","enrollment":269},{"nctId":"NCT05857891","phase":"NA","title":"The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2023-05-20","conditions":"Acute Respiratory Distress Syndrome","enrollment":40},{"nctId":"NCT04885647","phase":"PHASE2","title":"A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2021-03-12","conditions":"Renal Anemia of Chronic Kidney Disease","enrollment":60},{"nctId":"NCT02879305","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-28","conditions":"Anaemia, Aspergillosis, Allergic Bronchopulmonary","enrollment":2964},{"nctId":"NCT02745990","phase":"NA","title":"Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants","status":"UNKNOWN","sponsor":"Huiqing Sun","startDate":"2016-05","conditions":"Developmental Disabilities","enrollment":440},{"nctId":"NCT03400033","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-05","conditions":"Anaemia","enrollment":407},{"nctId":"NCT01010802","phase":"PHASE1","title":"Safety Study of Erythropoietin (EPO) in Parkinson's Disease","status":"COMPLETED","sponsor":"International Center for Neurological Restoration, Cuba","startDate":"2008-08","conditions":"Parkinson Disease","enrollment":10},{"nctId":"NCT03867071","phase":"NA","title":"Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2005-10","conditions":"Trauma","enrollment":60},{"nctId":"NCT03835507","phase":"PHASE1, PHASE2","title":"Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2016-06-20","conditions":"Amyotrophic Lateral Sclerosis","enrollment":64},{"nctId":"NCT01977573","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-31","conditions":"Anaemia","enrollment":252},{"nctId":"NCT01977482","phase":"PHASE2","title":"Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-01","conditions":"Anaemia","enrollment":216},{"nctId":"NCT01587924","phase":"PHASE2","title":"4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-23","conditions":"Anaemia","enrollment":80},{"nctId":"NCT03317210","phase":"PHASE4","title":"Intravenous Treatment of Anemia in Pregnancy","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2002-09-01","conditions":"Anemia","enrollment":50},{"nctId":"NCT03303573","phase":"","title":"Safety and Efficacy of Multiple EPO Injections in Children With Cerebral Palsy","status":"COMPLETED","sponsor":"Bundang CHA Hospital","startDate":"2013-01-01","conditions":"Cerebral Palsy","enrollment":164},{"nctId":"NCT03302338","phase":"PHASE1","title":"Simulated Amniotic Fluid Solution in Neonates Recovering From GIT Surgeries","status":"UNKNOWN","sponsor":"Rania Ali El-Farrash","startDate":"2015-07","conditions":"Necrotizing Enterocolitis","enrollment":40},{"nctId":"NCT03110341","phase":"PHASE3","title":"Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-04-10","conditions":"Premature Infants, Intracranial Hemorrhages, Periventricular Leukomalacia","enrollment":400},{"nctId":"NCT02075463","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2014-06-01","conditions":"Anemia","enrollment":15},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT03093506","phase":"EARLY_PHASE1","title":"Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2011-09","conditions":"Human Volunteers","enrollment":25},{"nctId":"NCT01800305","phase":"PHASE1","title":"PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2012-09","conditions":"Healthy","enrollment":150},{"nctId":"NCT02405637","phase":"PHASE1","title":"Simulated Amniotic Fluid In Preventing Feeding Intolerance and Necrotizing Enterocolitis VLBW Neonates","status":"UNKNOWN","sponsor":"Rania Ali El-Farrash","startDate":"2014-03","conditions":"Necrotizing Enterocolitis","enrollment":40},{"nctId":"NCT00313716","phase":"PHASE2, PHASE3","title":"Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury","status":"COMPLETED","sponsor":"Claudia Sue Robertson","startDate":"2006-04","conditions":"Anemia, Traumatic Brain Injury","enrollment":200},{"nctId":"NCT02036073","phase":"PHASE4","title":"Effect of Erythropoietin on Preterm Brain Injury","status":"COMPLETED","sponsor":"Zhengzhou Children's Hospital, China","startDate":"2009-01","conditions":"Premature Birth","enrollment":490},{"nctId":"NCT01441427","phase":"PHASE1, PHASE2","title":"Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2010-01","conditions":"Feeding Intolerance, Necrotizing Enterocolitis","enrollment":93},{"nctId":"NCT01392612","phase":"PHASE4","title":"Erythropoietin and Platelet Activation Markers","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-11","conditions":"Thrombosis, Hypertension","enrollment":12},{"nctId":"NCT00939978","phase":"NA","title":"Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Cardiac Surgery","enrollment":74},{"nctId":"NCT00910234","phase":"PHASE1, PHASE2","title":"Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2009-08","conditions":"Infant, Premature, Leukomalacia, Periventricular, Intraventricular Hemorrhage","enrollment":100},{"nctId":"NCT00593801","phase":"NA","title":"Erythropoietin Treatment in Extremely Low Birth Weight Infants","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"1998-05","conditions":"Infant, Low Birth Weight, Anemia","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yibiao"],"phase":"phase_3","status":"active","brandName":"rhEPO","genericName":"rhEPO","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rhEPO stimulates erythropoiesis by binding to the erythropoietin receptor. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}